Functional characterization of NTRK1 mutations identified in melanoma

Genes Chromosomes and Cancer

Volumn 53, Issue 10, 2014, Pages 875-880

  Miranda, Claudia ^a   Mazzoni, Mara ^a   Sensi, Marialuisa ^a   Pierotti, Marco A ^a   Greco, Angela ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

TYROSINE KINASE RECEPTOR; PROTEIN TYROSINE KINASE A;

3T3 CELL LINE; AMINO ACID SUBSTITUTION; ARTICLE; GENE; GENE EXPRESSION; GENE SEQUENCE; GENETIC TRANSFECTION; HELA CELL LINE; MELANOMA; MISSENSE MUTATION; MUTATIONAL ANALYSIS; NTRK1 GENE; NUCLEOTIDE SEQUENCE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; ANIMAL; GENETIC ASSOCIATION; GENETICS; HUMAN; METABOLISM; MOUSE; SKIN TUMOR;

ANIMALS; GENETIC ASSOCIATION STUDIES; HELA CELLS; HUMANS; MELANOMA; MICE; NIH 3T3 CELLS; POINT MUTATION; RECEPTOR, TRKA; SKIN NEOPLASMS;

EID: 84905723656     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.22200     Document Type: Article

References (21)

1. Barbacid M. 1995. Neurotrophic factors and their receptors. Curr Opin Cell Biol 7:148-155.
2. Cordon-Cardo C, Tapley P, Jing S, Nanduri V, O'Rorke E, Lamballe F, Kovary K, Klein R, Jones KR, Reichardt LF, Barbacid M. 1991. The trk tyrosine protein kinase mediates the mitogenic properties of nerve growth factor and neurotrophin-3. Cell 66:173-183.
3. Denkins Y, Reiland J, Roy M, Sinnappah-Kang ND, Galjour J, Murry BP, Blust J, Aucoin R, Marchetti D. 2004. Brain metastases in melanoma: Roles of neurotrophins. Neuro Oncol 6:154-165.
4. Flaherty KT, Fisher DE. 2011. New strategies in metastatic melanoma: Oncogene-defined taxonomy leads to therapeutic advances. Clin Cancer Res 17:4922-4928.
5. Florenes VA, Maelandsmo GM, Holm R, Reich R, Lazarovici P, Davidson B. 2004. Expression of activated TrkA protein in melanocytic tumors: Relationship to cell proliferation and clinical outcome. Am J Clin Pathol 122:412-420.
6. Geiger TR, Song JY, Rosado A, Peeper DS. 2011. Functional characterization of human cancer-derived TRKB mutations. PLoS One 6:e16871.
7. Greco A, Miranda C, Pierotti MA. 2010. Rearrangements of NTRK1 gene in papillary thyroid carcinoma. Mol Cell Endocrinol 321:44-49.
8. Hanks SK, Quinn AM, Hunter T. 1988. The protein kinase family: Conserved features and deduced phylogeny of the catalytic domains. Science 241:42-52.
9. Harada T, Yatabe Y, Takeshita M, Koga T, Yano T, Wang Y, Giaccone G. 2011. Role and relevance of TrkB mutations and expression in non-small cell lung cancer. Clin Cancer Res 17:2638-2645.
10. Hill VK, Gartner JJ, Samuels Y, Goldstein AM. 2013. The genetics of melanoma: Recent advances. Annu Rev Genomics Hum Genet 14:257-279.
11. Johnson DB, Sosman JA. 2013. Update on the Targeted Therapy of Melanoma. Curr Treat Options Oncol 14(2):280-292.
12. Kruttgen A, Schneider I, Weis J. 2006. The dark side of the NGF family: Neurotrophins in neoplasias. Brain Pathol 16:304-310.
13. Miranda C, Di Virgilio M, Selleri S, Zanotti G, Pagliardini S, Pierotti MA, Greco A. 2002a. Novel pathogenic mechanisms of congenital insensitivity to pain with anhidrosis genetic disorder unveiled by functional analysis of neurotrophic tyrosine receptor kinase type1/nerve growth factor receptor mutations. J Biol Chem 277:6455-6462.
14. Miranda C, Zanotti G, Pagliardini S, Ponzetto C, Pierotti MA, Greco A. 2002b. Gain of function mutations of RTK conserved residues display differential effects on NTRK1 kinase activity. Oncogene 21: 8334-8339.
15. Miranda C, Nucifora M, Molinari F, Conca E, Anania MC, Bordoni A, Saletti P, Mazzucchelli L, Pilotti S, Pierotti MA, Tamborini E, Greco A, Frattini M. 2012. KRAS and BRAF mutations predict primary resistance to imatinib in gastrointestinal stromal tumors. Clin Cancer Res 18:1769-1776.
16. Prickett TD, Agrawal NS, Wei X, Yates KE, Lin JC, Wunderlich JR, Cronin JC, Cruz P, Rosenberg SA, Samuels Y. 2009. Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4. Nat Genet 41:1127-1132.
17. Truzzi F, Marconi A, Lotti R, Dallaglio K, French LE, Hempstead BL, Pincelli C. 2008. Neurotrophins and their receptors stimulate melanoma cell proliferation and migration. J Invest Dermatol 128:2031-2040.
18. Vaishnavi A, Capelletti M, Le AT, Kako S, Butaney M, Ercan D, Mahale S, Davies KD, Aisner DL, Pilling AB, Berge EM, Kim J, Sasaki H, Park SI, Kryukov G, Garraway LA, Hammerman PS, Haas J, Andrews SW, Lipson D, Stephens PJ, Miller VA, Varella-Garcia M, Janne PA, Doebele RC. 2013. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med 19:1469-1472.
19. Vizioli MG, Sensi M, Miranda C, Cleris L, Formelli F, Anania MC, Pierotti MA, Greco A. 2010. IGFBP7: An oncosuppressor gene in thyroid carcinogenesis. Oncogene 29:3835-3844.
20. Whiteman DC, Pavan WJ, Bastian BC. 2011. The melanomas: A synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 24:879-897.
21. Wiesner T, He J, Yelensky R, Esteve-Puig R, Botton T, Yeh I, Lipson D, Otto G, Brennan K, Murali R, Garrido M, Miller VA, Ross JS, Berger MF, Sparatta A, Palmedo G, Cerroni L, Busam KJ, Kutzner H, Cronin MT, Stephens PJ, Bastian BC. 2014. Kinase fusions are frequent in Spitz tumours and spitzoid melanomas. Nat Commun 5:3116.